Global Adrenocorticotropic Hormone (ACTH) Market Size, Share, Forecast Report, 2020-2027

Warning: DOMDocument::loadHTML(): htmlParseEntityRef: no name in Entity, line: 47 in /home/multiwpmr/public_html/report-details.php on line 448

Warning: DOMDocument::loadHTML(): htmlParseEntityRef: no name in Entity, line: 50 in /home/multiwpmr/public_html/report-details.php on line 448
The report provides rational insights along with historical and forecast data to aid in better understanding of the Global Adrenocorticotropic Hormone (ACTH) Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of the Adrenocorticotropic Hormone (ACTH) market. This study also provides a detailed overview of the opportunities along with the current trends observed in the target market.

According to the report, the global adrenocorticotropic hormone (ACTH) market was valued at US$ 1.47 Bn in 2018 and is projected to expand at a CAGR of ~4% from 2019 to 2027. Multiple applications and rise in number of patients with chronic diseases are the major factors anticipated to drive the global adrenocorticotropic hormone (ACTH) market from 2019 to 2027.

Multiple Applications and Rise in Prevalence of Chronic Diseases to Drive Global Market

H.P. Acthar Gel was the primary corticotropin product from Questcor Pharmaceuticals, Inc., which was acquired by Mallinckrodt in August 2014. The U.S. FDA approved Acthar for the treatment of 19 indications. The rate of infantile spasm is estimated to be 2.5 to 6.0 cases per 10,000 live births. Its prevalence rate is 1.5 to 2.0 cases per 10,000 children aged 10 years or younger, based on data published in the National Organization for Rare Disorders, Inc. According to the Centers for Disease Control and Prevention (CDC), about 23% adults in the U.S., which is more than 54 million people, have arthritis. The disease is expected to affect 78 million adults in the country by 2040.

According to data published in the National Center for Biotechnology Information in 2019, the estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 people, and approximately 1.2 million to 1.9 million persons are at risk per year. Adrenocorticotropic hormone (ACTH) as a treatment for proteinuria due to nephrotic syndrome (NS) has re-emerged in the last decade. Nephrotic syndrome is one of the most common chronic renal diseases in children. It has an incidence of 2 to 7 per 100,000 population and a prevalence of 16 per 100,000, well above the 1 per 1 million incidence of chronic renal failure in children. Hence, rise in cases of target diseases and applications of corticotropin in various indications boost the growth of the global market.

The report covers major players operating in the market along with the key strategies implemented to achieve a competitive edge against a majority of the vendors which provides a competitive outlook of the industry. The competitive landscape further includes details about different players and their position on a global and a local level is also explained in detail in this compiled study. These insights were prepared through mapping business strategies and products that offer high revenue generation capacities. Key players of the global Adrenocorticotropic Hormone (ACTH) market are included as given below:

Mallinckrodt plc

Pfizer, Inc.

Novartis AG

Mylan N.V.,

Hikma Pharmaceuticals plc

The global Adrenocorticotropic Hormone (ACTH) market has been segmented as below:

� Adrenocorticotropic Hormone (ACTH) Market, by Source

o Natural

o Synthetic

� Adrenocorticotropic Hormone (ACTH) Market, by Indication

o Rheumatology

o Neurology

o Nephrotic Syndrome

o Ophthalmology

o Others

� Adrenocorticotropic Hormone (ACTH) Market, by Distribution Channel

o Hospital Pharmacies

o Retail Pharmacies

o Online Pharmacies

� Adrenocorticotropic Hormone (ACTH) Market, by Region

o North America

? U.S.

? Canada

o Europe

? U.K.

? Germany

? France

? Spain

? Italy

? Rest of Europe

o Asia Pacific

? Japan

? China

? India

? Australia

? Rest of Asia Pacific

o Latin America

? Brazil

? Mexico

? Rest of Latin America

o Middle East & Africa

? GCC Countries

? South Africa

? Rest of Middle East & Africa

Reasons to Purchase this Report:

Estimates Adrenocorticotropic Hormone (ACTH) development trends with SWOT analysis

� Detailed business profiles including product offerings, recent developments, key financial information, and strategies employed by main market players

� Analysis of various regions and countries that includes the demand and supply based actions, which consequently have a major influence on the market's expansion

� Market dynamics scenario, along with growth opportunities for players in the years to come

� Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the mentioned forecast period

� Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects